Biotest AG — Board/Management Information 2004

Feb 3, 2004

News Details

Corporate | 3 February 2004 10:03

Biotest AG : Management changes at Biotest

Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– Management changes at Biotest Dreieich, February 3, 2004. Biotest AG, which specialises in the development, production and marketing of therapeutics and diagnostic systems and focuses on clinical immunology, haematology and intensive care, is making changes to two top management positions. Dr. Manfred Hübener (48), who has been the Managing Board member responsible for Finance and Central Services since June 2000, leaves the company by mutual agreement on 6th February. Dr. Michael Ramroth (42) will take on his role as Finance Director. Dr. Ramroth was employed by MG Technologies AG in various management functions for over 13 years: most recently, from 2000 to 2003, he was the Managing Board member responsible for business development. Also in February, Dr. Joachim Herborg will occupy the vacant position of Marketing and Sales department manager at Biotest. Dr. Herborg (51) has many years of experience in marketing plasma products as a result of his work over 17 years at Aventis Behring, a large, international plasma processor. In recent years his role was sales manager for Germany and Switzerland. Biotest AG The Board of Managing Directors end of message, (c)DGAP 03.02.2004 ——————————————————————————– WKN: 522720; ISIN: DE0005227201; Index: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart 031003 Feb 04